DK0485431T3 - Partielle agonister for det strychnin-ufølsomme glycin-modulations-site i N-methyl-D-aspartat-receptorkomplekset som neurofarmakologiske midler - Google Patents

Partielle agonister for det strychnin-ufølsomme glycin-modulations-site i N-methyl-D-aspartat-receptorkomplekset som neurofarmakologiske midler

Info

Publication number
DK0485431T3
DK0485431T3 DK90911501.6T DK90911501T DK0485431T3 DK 0485431 T3 DK0485431 T3 DK 0485431T3 DK 90911501 T DK90911501 T DK 90911501T DK 0485431 T3 DK0485431 T3 DK 0485431T3
Authority
DK
Denmark
Prior art keywords
methyl
receptor complex
strychnine
partial agonists
aspartate receptor
Prior art date
Application number
DK90911501.6T
Other languages
Danish (da)
English (en)
Inventor
Phil Skolnick
Anita Lewin
Juan-Carlos Marvizon
Kenner Rice
James Monn
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of DK0485431T3 publication Critical patent/DK0485431T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK90911501.6T 1989-08-08 1990-08-02 Partielle agonister for det strychnin-ufølsomme glycin-modulations-site i N-methyl-D-aspartat-receptorkomplekset som neurofarmakologiske midler DK0485431T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/390,745 US6017957A (en) 1989-08-08 1989-08-08 Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents

Publications (1)

Publication Number Publication Date
DK0485431T3 true DK0485431T3 (da) 1997-08-25

Family

ID=23543754

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90911501.6T DK0485431T3 (da) 1989-08-08 1990-08-02 Partielle agonister for det strychnin-ufølsomme glycin-modulations-site i N-methyl-D-aspartat-receptorkomplekset som neurofarmakologiske midler

Country Status (10)

Country Link
US (1) US6017957A (de)
EP (1) EP0485431B1 (de)
JP (1) JP2598570B2 (de)
AT (1) ATE148989T1 (de)
AU (1) AU639252B2 (de)
CA (1) CA2059526C (de)
DE (1) DE69029967T2 (de)
DK (1) DK0485431T3 (de)
ES (1) ES2097151T3 (de)
WO (1) WO1991001729A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
WO1996015788A1 (en) * 1994-11-23 1996-05-30 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
IL118657A0 (en) * 1996-06-14 1996-10-16 Arad Dorit Inhibitors for picornavirus proteases
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6515103B1 (en) 1996-07-22 2003-02-04 University Of Utah Research Foundation Conantokins
EP0964691A4 (de) 1996-07-22 2002-10-30 Cognetix Inc Verwendung von conantokine
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US20070179174A1 (en) * 2003-12-08 2007-08-02 Bachurin Sergei O Methods and compositions for slowing aging
RU2283108C2 (ru) * 2003-12-08 2006-09-10 Сергей Олегович Бачурин ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
CN1293868C (zh) * 2004-12-29 2007-01-10 朱旭祥 α－环丙氨酸在制备治疗心脑血管疾病药物中的应用
EP1893576A4 (de) * 2005-05-27 2010-03-17 Univ Kingston Behandlung von proteinfaltungsstörungen
WO2007041697A2 (en) * 2005-10-04 2007-04-12 Medivation, Inc. Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
US7531572B2 (en) * 2006-07-28 2009-05-12 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554017A (en) * 1978-06-03 1985-11-19 Bayer Aktiengesellschaft Method and compositions for regulating plant growth using cycloalkane-carboxylic acid compounds
FR2508033A1 (fr) * 1981-06-23 1982-12-24 Fabre Sa Pierre Aryl-1 aminomethyl-2 cyclopropanes carboxylates (z), leur preparation et leur application en tant que medicaments utiles dans le traitement d'algies diverses
US4491589A (en) * 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
US4746653A (en) * 1986-02-28 1988-05-24 Ciba-Geigy Corporation Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex

Also Published As

Publication number Publication date
AU639252B2 (en) 1993-07-22
ATE148989T1 (de) 1997-03-15
AU6143490A (en) 1991-03-11
EP0485431A4 (en) 1992-08-12
CA2059526A1 (en) 1991-02-09
DE69029967T2 (de) 1997-05-28
ES2097151T3 (es) 1997-04-01
WO1991001729A1 (en) 1991-02-21
EP0485431A1 (de) 1992-05-20
CA2059526C (en) 1996-12-17
US6017957A (en) 2000-01-25
JPH05501868A (ja) 1993-04-08
JP2598570B2 (ja) 1997-04-09
EP0485431B1 (de) 1997-02-19
DE69029967D1 (de) 1997-03-27

Similar Documents

Publication Publication Date Title
DK0485431T3 (da) Partielle agonister for det strychnin-ufølsomme glycin-modulations-site i N-methyl-D-aspartat-receptorkomplekset som neurofarmakologiske midler
Singh et al. Modulation of seizure susceptibility in the mouse by the strychnine-insensitive glycine recognition site of the NMDA receptor/ion channel complex
NO951613L (no) Ikke-peptidyl tachykinin reseptorantagonister
DE69533180D1 (de) Steroidrezeptor-Modulator Verbindungen und Methoden
LU92292I2 (fr) Combinaison d'oxycodone en tant que composant A etde naloxone en tant que composant B sous toutes l es formes protégés par le brevet de base
NZ235877A (en) Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
CA2085135A1 (en) Treatment of Mood Disorders with Functional Antagonists of the Glycine/NMDA Receptor Complex
ATE301994T1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda- antagonist
PT918774E (pt) Compostos moduladores do receptor para androgenio e metodos
DE69720745D1 (de) Therapeutische kombinationen von rar-antagonisten und rxr-agonisten
YU7797A (sh) Kombinovana terapija za osteoporozu
EP0738152A4 (de) Verwendung von 2-hydroxy-5-phenylazobenzoesäure-derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
BG100930A (bg) Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения
DE69317418D1 (de) PHARMAZEUTISCHE ZUSAMMENSETZUNGEN VON 5HT1 AGONISTISCHEN ALKYL SULPHONAMIDENFüR REKTALE VERABREICHUNGEN
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
ATE81775T1 (de) Pharmazeutische zusammensetzungen.